SASAI has been proposed and is developed under the lead of the EANM Drug Development and Radiopharmacy Committee . An international group of experts has been nominated through an open call to help in the planning and facilitation of the project. The project is approved and supported by the EANM Board who strongly believes in the potential of SASAI. The project management is handled through EARL (EANM Research GmbH), a full EANM subsidiary.
A standardised audit report, produced by independent professional auditors, is available for interested parties at the EARL Office against a service fee. Download and complete the corresponding audit report order form (see above), and remit it via email to email@example.com to place your order.
The cost for the currently available reports can be found in the audit report order form (see above).
To comply with legal regulations a possibility for producers is foreseen to take an active influence in the audit during the planning phase. Once the period for contributions is closed, interested parties may still purchase the report.
To share your top two priorities of suppliers and their products, please feel free to complete the following survey, as the community will greatly benefit from your feedback. Here you can access the survey.
You are responsible on a national level to contact your authorities to investigate the acceptance of such a community-based audit. From the feedback that the SASAI working group was able to gather up to now, authorities highly appreciate the approach.
SASAI has been under development by the EANM since 2018 and has now completed its feasibility study phase by completing the proof of concept audit at ABX GmbH. Further audits are under development.